Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Heartland Group Holdings (HGH) / FY24

PBT fell 22.0% on near-flat revenue as impairment charges bit hard

Revenue growth of just 0.2% left no buffer when provisions surged, driving a 22.0% PBT decline and compressing ROE to 6.0% from 9.3%.

Financials / Banking and finance

HGH revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $172.3m, versus $322.9m in FY25.

HGH Operating profit margin

Operating profit margin across covered periods.

↗
Loading chart...
HY26 was 45.2%, versus 36.8% in HY25.

HGH operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $299.5m, versus $673.2m in FY25.

HGH working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY24 was -$0.2m, versus $0.4m in FY23.
Release date
29 August 2024
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

FY24 vs FY23

Revenue

$290.4m

+0.2% ↑ vs $289.8m

Net profit after tax

$74.5m

-22.3% ↓ vs $95.9m

Net cash inflow from operating activities

$928.4m

n/m ↑ vs $42.7m

Full-year dividend per share

7.0c

-39.1% ↓ vs 11.5c

Profit before tax

$104.5m

-22.0% ↓ vs $134m

Cash and cash equivalents

$629.6m

+102.1% ↑ vs $311.5m

Total assets

$9.3b

n/m ↑ vs $7.7m

What changed

Revenue was essentially flat at NZ$290.4m (+0.2%), well below the company's historical baseline range of 3.3%–11.7% growth and 8.5 percentage points below the historical mean of 8.7%, leaving earnings highly exposed to any cost or credit pressure

With operating profit down 6.5% to NZ$151.3m and a late-cycle surge in impairment provisions — including a NZ$10.1m increase concentrated in Asset Finance, Motor Finance, and Rural portfolios — PBT fell 22.0% to NZ$104.5m and NPAT fell 22.3% to NZ$74.5m. Management disclosed that NZ$28.2m in one-off or non-cash technical items weighed on NPAT and that the result fell approximately 4.9% short of its own guidance.

ROE declined to 6.0% from 9.3% in FY23, now at the lower edge of the company's historical range and 2.1 percentage points below the historical mean of 8.1%, reflecting both compressed earnings and an expanded equity base.

Pre-lease free cash flow of NZ$900.3m was substantially above the historical range (mean NZ$138.2m, prior range NZ$-272.1m to NZ$668.8m), driven by a sharp swing in operating cash flows from NZ$42.7m in FY23 to NZ$928.4m in FY24. This is a banking-sector cash flow and reflects loan book and funding movements rather than recurring operational cash generation.

What matters

Impairment pressure is the dominant earnings driver

Capital raise is explicitly linked in the filing to balance-sheet leverage, with NZ$210m capital raised.

The late escalation in provisions was the proximate cause of the guidance miss and the key reason PBT compressed so sharply relative to near-flat revenue. Management attributed this primarily to Asset Finance, Motor Finance, and Rural portfolios, consistent with the broader New Zealand economic environment. Until provision build stabilises, underlying net interest income is likely to remain masked by credit-cost noise.

Revenue stagnation reveals NIM pressure. Revenue growth of 0.2% is anomalously low against a historical mean of 8.7%. Receivables grew 6.4%, implying that net interest margin compression has materially offset volume growth. The prior period disclosed an NIM of 3.97%; FY24 margin has not been restated here at comparable precision, but the combination of pre-acquisition deposit-raising and funding cost dynamics clearly weighed on spread income.

ROE and capital efficiency have weakened. At 6.0%, ROE is at the lower edge of the company's historical range and below the historical mean. An expanded equity base following the April 2024 capital raise amplifies the near-term dilution effect on returns. This matters because the strategic rationale for the acquisition depends on the Australian platform generating returns that offset current dilution — a result that is not yet visible in the FY24 numbers.

Expectations

No formal forward earnings guidance is disclosed in the release

Management described the longer-term outlook as positive and noted that receivables growth of 6.4% demonstrates resilience in a challenging environment. However, the guidance miss — attributed to late provision increases — and management's acknowledgement of continued volatility through the remainder of calendar 2024 suggest that impairment risk has not fully cleared. Receivables growth in Motor Finance (+3.8%) was achieved despite a 12.7% decline in dealer car sales, and Reverse Mortgages grew strongly in both markets, which provides some volume support for FY25.

The second-half NPAT of approximately NZ$37.0m implied by HY24 context is broadly in line with the first half (NZ$37.6m), indicating no meaningful second-half recovery. With ROE already at the lower edge of the historical range, earnings improvement in FY25 is contingent on impairment normalisation and margin recovery from lower funding costs — neither of which is assured from this result alone.

Quality of result

Challenger Bank acquisition is explicitly linked in the filing to statutory earnings quality, with NZ$23.2m acquisition price

The headline earnings decline of 22.0% at PBT level is genuine in the sense that neither the tax rate (28.7% versus 28.5% prior) nor any discontinued-operation effect explains the gap. The NZ$28.2m one-off and non-cash technical items cited by management are disclosed but not fully itemised in the excerpts available, which limits the ability to assess how much of the PBT decline is recurring. The late NZ$10.1m provision increase, while arguably a timing acceleration, reflects real credit deterioration rather than an accounting distortion.

The large operating cash flow figure of NZ$928.4m and pre-lease FCF of NZ$900.3m are above the historical range by a significant margin, but for a finance company these figures primarily reflect changes in lending and deposit balances rather than underlying profit generation. The FCF-to-NPAT ratio of approximately 1,208% underscores that this cash movement is structural rather than a quality signal about reported earnings. The full-year dividend of 7.0 cents per share compares to 11.5 cents in FY23; the payout ratio against NPAT of 71.1% is below the historical mean of 82.4%, indicating a deliberate reduction in capital distribution in the context of balance sheet expansion.

Unresolved

Open questions

What is the current net interest margin for FY24, and by how much did funding costs from pre-acquisition deposit-raising compress spread income relative to the prior year?
Will the late-cycle provision increases in Asset Finance, Motor Finance, and Rural portfolios prove to be a one-period event, or does arrears data suggest further impairment in HY25?
How is the acquired Australian banking platform performing on a standalone basis, and what timeline does management expect before the acquisition is accretive to group ROE?
Does management have a revised earnings guidance range for FY25, and what impairment expense ratio is embedded in that view?
Whether the NZ$28.2m in one-off and non-cash technical items can be expected to reverse or partially reverse in FY25, and what portion relates to acquisition-related costs versus other adjustments.

This briefing cannot assess the quality of the acquired Australian banking book, the adequacy of current provision coverage ratios, or the trajectory of net interest margin without more granular loan portfolio and funding-cost data than is available in this release.

Chat

Ask about HGH FY24

Ask follow-up questions about Heartland Group Holdings's FY24 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about HGH FY24

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Heartland Group Holdings's FY24 result.

What is the current net interest margin for FY24, and by how much did funding costs from pre-acquisition deposit-raising compress spread income relative to the prior year?Why does "Impairment pressure is the dominant earnings driver" matter?How strong was the cash and earnings quality in FY24?What should I watch next for HGH after FY24?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Heartland FY2024 – Financial Statements

FY24 / financial report↗

Heartland FY2024 – Investor Presentation

FY24 / results presentation↗

Heartland FY2024 – Results Announcement

FY24 / results release↗

Heartland FY2024 – Results Announcement Template

FY24 / results announcement↗

Prior comparable period

Heartland FY23 - HGH Financial Statements

FY23 / financial report↗

Heartland FY23 - Investor Presentation

FY23 / results presentation↗

Heartland FY23 - NZX Results Announcement

FY23 / results release↗

Heartland FY23 - NZX Results Announcement Template

FY23 / results announcement↗

Interim context

Heartland 1H24 - HGH Financial Statements

HY24 / financial report↗

Heartland 1H24 - Investor Presentation

HY24 / results presentation↗

Heartland 1H24 - Results Announcement

HY24 / results release↗

Heartland 1H24 - Results Announcement Template

HY24 / results announcement↗

Related insights

Cross-company views selected from the metrics in this briefing.

Dividend coverage and payout pressure

Company-disclosed payout ratio is 55.0% on a NPAT basis, with NPAT payout at 71.1%.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.3pp.

→

ROE and capital efficiency

ROE was 6.0%, -3.3pp versus the prior comparable period.

→

Revenue growth context

Revenue growth was 0.2% for this reporting period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when HGH publishes next

Get the next Heartland Group Holdings briefing and related NZX reporting-season updates by email.